Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

Introduction

Note 1: Central nervous system (CNS) includes the following primary sites: Cerebral meninges C700; spinal meninges C701; meninges NOS C709; brain C710-C719; cauda equina C721; olfactory nerve C722; optic nerve C723; acoustic nerve C724; cranial nerve NOS C725; overlapping lesion of brain and central nervous system C728; nervous system NOS C729; pituitary gland C751; craniopharyngeal duct C752; pineal gland C753. These rules also include nerve roots C470, C473, C475, C476.

Note 2: Malignant CNS neoplasms have a separate set of rules.

Note 3: 2007 MPH Rules and 2018 Solid Tumor Rules are used based on date of diagnosis.
- Tumors diagnosed 01/01/2007 through 12/31/2017: Use 2007 MPH Rules
- Tumors diagnosed 01/01/2018 and later: Use 2018 Solid Tumor Rules
- The original tumor diagnosed before 1/1/2018 and a subsequent tumor diagnosed 1/1/2018 or later in the same primary site: Use the 2018 Solid Tumor Rules.

Note 4: Non-malignant central nervous system (CNS) neoplasms (previously called benign and borderline) are reportable for cases diagnosed 1/1/2004 and later.

Note 5: Pilocytic astrocytoma/juvenile pilocytic astrocytoma is reportable in North America as a malignant neoplasm- 9421/3.
- WHO and IARC designate pilocytic astrocytoma as a synonym for optic glioma. When the primary site is optic nerve, the behavior is non-malignant.

Note 6: Tables and rules refer to ICD-O rather than ICD-O-3. The version is not specified to allow for updates. Use the currently approved version of ICD-O.

Note 7: For those sites/histologies which have recognized biomarkers, the biomarkers may aid in the identification of histologic type. Currently, there are clinical trials being conducted to determine whether these biomarkers can be used to identify multiple primaries. Follow the Multiple Primary Rules; do not code multiple primaries based on biomarkers.

Equivalent or Equal Terms

These terms can be used interchangeably:

- And; with
  Note: “And” and “with” are used as synonyms when describing multiple histologies within a single tumor.
- Atypical; uncertain behavior /1
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

- Cerebrospinal fluid; CSF
- Dermoid; dermoid cyst
- Dura; meninges
- Extradural; not within the meninges; within the cranium; within the skull but not within the cerebral meninges
- Extramedullary; outside medulla oblongata C700
- Intracranial; within the skull, within the cranium
- Intradural; between layers of the cerebral meninges; C700
- Intradural-extramedullary; within the spinal canal but outside of the nerves
- Intraspinal; occurring within the spinal column especially the vertebral canal; spinal nerve roots
- Non-malignant is synonymous with:
  - /0 Benign
  - /1 Uncertain whether benign or malignant; borderline malignancy; low malignant potential; uncertain malignant potential
- Site; topography
- Subarachnoid space; between the arachnoid mater and the pia mater of spinal meninges
- Type; subtype; variant
- Tumor; mass; tumor mass; lesion; neoplasm
  - The terms tumor, mass, tumor mass, lesion, and neoplasm are not used in a standard manner in clinical diagnoses, scans, or consults. Disregard the terms unless there is a physician’s statement that the term is a non-malignant tumor/neoplasm
  - These terms are used ONLY for determining multiple primaries
  - DO NOT USE these terms for casefinding or determining reportability
- WHO Grade 1; Non-malignant /0 and /1

Terms that are NOT Equivalent or Equal

This is a term that is not equivalent. There are no casefinding implications.

- **Component** is not equivalent to subtype/variant
  
  *Note:* Component is only coded when the pathologist specifies the component as a second carcinoma.
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

Changes from 2007 MPH Rules

These changes are effective with cases diagnosed 1/1/2018 and later.

1. Clarifications:
   - The following meningiomas are reportable: Intraosseous, cavernous sinus, and sphenoid wing.
   - Multiple cerebral meningiomas are a single primary.
   - Multiple brain tumors (same histology) are a single primary.
   - Bilateral optic nerve gliomas/pilocytic astrocytomas are a single primary.
   - Laterality is not used to determine multiple primaries.
   - Timing is not used to determine multiple primaries.
   - The brain C710-C719 is a single primary site.
   - Neurofibromatosis NOS, Neurofibromatosis 1 (NF1), and Neurofibromatosis 2 (NF2) are syndromes and not reportable neoplasms.

2. The 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (CNS) contains newly recognized histologies and subtypes/variants. New codes/terms are identified by asterisks (*) in Tables 5 and 6 in the Terms and Definitions.

Reportability Criteria for Non-Malignant CNS Neoplasms

CNS neoplasms must meet all three criteria/conditions below to be reported as non-malignant:
1. The behavior must non-malignant /0 or /1
   A. Pathology designates the tumor as non-malignant (/0 or /1) OR
   B. The tumor is a WHO Grade I (See Section 1: Table 1) AND
      Note 1: Always code the behavior code reported by the pathologist.
      Note 2: Never report a malignant /3 behavior code for a meningioma based on tumor extension to brain, skin of scalp, or other regional organs/tissue. Non-malignant CNS tumors can extend to the regional tissue and bone. Tumor extension is usually equivalent to atypical meningioma 9539/1.
2. The primary site must be reportable (See Section 2: Table 3 and Table 4) AND
3. The histology must be reportable (See Section 2: Table 5 and Table 6)
Information is presented in the general order in which a case is abstracted.

**Section 1: Behavior Code**
- **Priority Order** for Using Documentation to Assign Behavior
- **Table 1:** WHO Grades of Select CNS Neoplasms

**Section 2: Reportable Primary Sites and Histologies.**
- **Priorities for Coding Primary Site**
- **Reportable Primary Site Groups**
- **Table 2:** Reportable Primary Sites
- **Table 3:** Reportability of Non-Malignant Cranial Nerve (CN) Tumors (defines which portions of the cranial nerves are reportable)
- **Table 4:** Non-Reportable Neoplasms
- **Table 5:** Histologic Types of Non-Malignant Intracranial (Brain and Gland) Tumors
- **Table 6:** Specific Histologies, NOS, and Subtypes/Variants
  - **Note:** It is important to understand that non-malignant neoplasms do occur within the brain tissue.

**Section 3: Additional Information to Complete Abstract**
- **Conflicting information on Pathology report(s)**
- **Table 7:** Paired Sites
- **Table 8:** Non-malignant CNS Tumors with the Potential of Transforming to Malignant Behavior
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

Section 1: Behavior Code

Note: Behavior determines which set of CNS rules should be used: malignant or non-malignant.

Instructions for using source documentation to determine behavior are in priority order. Start with Instruction 1 and STOP when you reach the instruction that applies to the case being abstracted. For example, when the resection pathology specifies behavior, use Instruction 1. Do not code the behavior using Instructions 2-5.

Priority Order for Using Documentation to Assign Behavior

1. Pathology: Tissue from resection in the following priority order:
   A. Use the pathologist’s description of behavior
      Note: Never change behavior described by pathologist
   B. Cases are reportable as non-malignant when pathology states a WHO Grade 1
   C. WHO Grade 2 may be either non-malignant or malignant. Use the pathologist’s description of behavior (priority #1a)
2. Pathology: Tissue from biopsy
3. Cytology (usually cerebrospinal fluid)
4. Physician’s documentation (no pathology report) in the following priority order:
   A. Tumor Board
   B. Documentation of original diagnosis/tumor behavior
      Example: Biopsy or resection was done at a different institution; pathology report is not in the medical record. Oncology consult states biopsy was done in a different facility and cites pathology from biopsy including the behavior as benign, borderline, non-malignant or WHO Grade 1.
   C. Documentation of behavior, no mention of original diagnosis
      Example: Biopsy or resection was done at a different institution; pathology report is not in the medical record. Physician documents the behavior as benign, borderline, non-malignant, or WHO Grade 1, but does not cite/mention original pathology report as source of behavior classification.
5. Scans: Use behavior information from imaging in the following priority order:
   A. MRI
   B. CT
   C. PET
   D. Angiogram
6. When above instructions do not apply, use Table 1 below to determine behavior.
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

Table 1: WHO Grades of Select CNS Neoplasms

Note 1: See the SEER and COC Manuals for instructions on coding grade for CNS tumors.

Note 2: The table does not contain all neoplasms that may occur in the CNS.

Table Instructions
1. Use non-malignant CNS rules for all WHO Grade 1 (always non-malignant)
2. Go to the malignant CNS rules for all WHO Grade 3 and 4
3. Go to Instructions for Identifying and Assigning Behavior to determine whether WHO Grade 2 neoplasms are non-malignant or malignant. Use the appropriate set of rules.

Column 1 contains the histology term
Column 2 contains the WHO Grade assigned based on the histology and molecular features of that histology

<table>
<thead>
<tr>
<th>Histology</th>
<th>WHO Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anaplastic (malignant) meningioma</td>
<td>3</td>
</tr>
<tr>
<td>Anaplastic astrocytoma, IDH mutant</td>
<td>3</td>
</tr>
<tr>
<td>Anaplastic ependymoma</td>
<td>3</td>
</tr>
<tr>
<td>Anaplastic ganglioglioma</td>
<td>3</td>
</tr>
<tr>
<td>Anaplastic oligodendroglioma IDH mutant and 1p/19q-codeleted</td>
<td>3</td>
</tr>
<tr>
<td>Anaplastic pleomorphic xanthroastrocytoma</td>
<td>3</td>
</tr>
<tr>
<td>Angiocentric glioma</td>
<td>1</td>
</tr>
<tr>
<td>Atypical choroid plexus papilloma</td>
<td>2</td>
</tr>
<tr>
<td>Atypical meningioma</td>
<td>2</td>
</tr>
<tr>
<td>Atypical teratoid/rhabdoid tumor</td>
<td>4</td>
</tr>
<tr>
<td>Central neurocytoma</td>
<td>2</td>
</tr>
<tr>
<td>Cerebellar liponeurocytoma</td>
<td>2</td>
</tr>
<tr>
<td>Choroid glioma of third ventricle</td>
<td>2</td>
</tr>
<tr>
<td>Choroid plexus carcinoma</td>
<td>3</td>
</tr>
</tbody>
</table>
## Non-Malignant CNS Solid Tumor Rules 2018

Updated 8/13/2018

<table>
<thead>
<tr>
<th>Histology</th>
<th>WHO Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choroid plexus papilloma</td>
<td>1</td>
</tr>
<tr>
<td>CNS embryonal tumor NOS</td>
<td>4</td>
</tr>
<tr>
<td>CNS embryonal tumor with rhabdoid features</td>
<td>4</td>
</tr>
<tr>
<td>Craniopharyngioma</td>
<td>1</td>
</tr>
<tr>
<td>Desmoplastic infantile astrocytoma and ganglioglioma</td>
<td>1</td>
</tr>
<tr>
<td>Diffuse astrocytoma, IDH mutant</td>
<td>2</td>
</tr>
<tr>
<td>Diffuse midline glioma, H3K27M-mutant</td>
<td>4</td>
</tr>
<tr>
<td>Dysembryoplastic neuroepithelial tumor</td>
<td>1</td>
</tr>
<tr>
<td>Dysplastic gangliocytoma of cerebellum (D=Lhemitte-Duclos)</td>
<td>1</td>
</tr>
<tr>
<td>Ependymoma</td>
<td>2</td>
</tr>
<tr>
<td>Ependymoma, RELA fusion-positive</td>
<td>2 or 3</td>
</tr>
<tr>
<td><strong>Note:</strong> Tissue/pathology reports or CAP report will specify whether this is WHO Grade 2 or 3</td>
<td></td>
</tr>
<tr>
<td>Extraventricular neurocytoma</td>
<td>2</td>
</tr>
<tr>
<td>Gangliocytoma</td>
<td>1</td>
</tr>
<tr>
<td>Glioblastoma, IDH mutant</td>
<td>4</td>
</tr>
<tr>
<td>Glioblastoma, IDH wildtype</td>
<td>4</td>
</tr>
<tr>
<td>Granular cell tumor</td>
<td>1</td>
</tr>
<tr>
<td>Hemangioblastoma</td>
<td>1</td>
</tr>
<tr>
<td>Malignant peripheral nerve sheath tumor (MPNST)</td>
<td>2, 3, or 4</td>
</tr>
<tr>
<td><strong>Note:</strong> Tissue/pathology reports or CAP report will specify whether this is WHO Grade 2, 3, or 4</td>
<td></td>
</tr>
<tr>
<td>Medulloblastoma (including all subtypes)</td>
<td>4</td>
</tr>
<tr>
<td>Medullopithelioma</td>
<td>4</td>
</tr>
<tr>
<td>Meningioma</td>
<td>1</td>
</tr>
<tr>
<td>Myxopapillary ependymoma</td>
<td>1</td>
</tr>
<tr>
<td>Neurofibroma</td>
<td>1</td>
</tr>
<tr>
<td>Oligodendroglioma IDH mutant and 1p/19q-codeleted</td>
<td>2</td>
</tr>
<tr>
<td>Papillary gliöneuronal tumor</td>
<td>1</td>
</tr>
<tr>
<td>Papillary tumor of the pineal region</td>
<td>2 or 3</td>
</tr>
</tbody>
</table>

Jump to [Multiple Primary Rules](#)  
Jump to [Histology Coding Rules](#)  
Non-Malignant CNS Solid Tumor Rules 2018  
Updated 8/13/2018
<table>
<thead>
<tr>
<th>Histology</th>
<th>WHO Grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Perineuroma</td>
<td>1</td>
</tr>
<tr>
<td>Pilocytic astrocytoma</td>
<td>1</td>
</tr>
<tr>
<td>Pineal parenchymal tumor of intermediate differentiation</td>
<td>2 or 3</td>
</tr>
<tr>
<td>Pineoblastoma</td>
<td>4</td>
</tr>
<tr>
<td>Pineocytoma</td>
<td>1</td>
</tr>
<tr>
<td>Pituicytoma</td>
<td>1</td>
</tr>
<tr>
<td>Pleomorphic xanthroastrocytoma</td>
<td>2</td>
</tr>
<tr>
<td>Rosette-forming glioneuronal tumor</td>
<td>1</td>
</tr>
<tr>
<td>Schwannoma</td>
<td>1</td>
</tr>
<tr>
<td>Solitary fibrous tumor/hemangiopericytoma</td>
<td>1, 2, or 3</td>
</tr>
<tr>
<td>Spindle cell oncocytoma</td>
<td>1</td>
</tr>
<tr>
<td>Subependymal giant cell astrocytoma</td>
<td>1</td>
</tr>
<tr>
<td>Subependymoma</td>
<td>1</td>
</tr>
</tbody>
</table>
After determining behavior code, the next step is to confirm both the primary site and the histology are reportable.

**Note 1:** Tumors of the peripheral nerve roots and spinal meninges are reportable. The nerve roots are located within the spinal meninges C701.
- Non-malignant tumors of the extradural peripheral nerves are not reportable because they are not within the CNS.
- See the Reportable Primary Site Groups section for instructions on coding primary site for peripheral nerve roots.

**Note 2:** The following non-malignant meningiomas are reportable:
- **Intraosseous**
  - **Note:** The dura layer of the meninges contacts the endosteum of the bones of the skull. The primary site for intraosseous meningioma is cranial meninges C700
- **Sphenoid wing**
  - **Note 1:** Sphenoid wing meningiomas arise in the cranial meninges C700 which covers the bony structure called the sphenoid wing
  - **Note 2:** The term “sphenoid wing meningioma” is used to identify the location of the meningioma because sphenoid wing meningiomas may be very invasive, spreading to the dura of the frontal, temporal and orbital regions.
- **Cavernous sinus**
  - **Note 1:** Cavernous sinus is located between the endosteal and meningeal layers of the dura.
  - **Note 2:** There is no ICD-O site code for cavernous sinus because tumors do not arise in the sinus itself; the primary sites are:
    - The cranial nerves passing through the sinus (trochlear, abducent C725) OR
    - The cerebral meninges/dura C700 covering the cranial nerve

**Priorities for Coding Primary Site**

**Note 1:** Always check the operative report(s) which will have information on whether the surgery or biopsy was intracranial (inside the cranium/skull) or intraspinal (within the dura/emeninges covering the spinal cord)

**Note 2:** Code the specific primary site. Use an NOS site code only when a specific site is not known.

Use the list on the next page in hierarchical order:
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

1. **Resection**
   A. Operative report(s)
   B. Pathology report(s)
2. **Biopsy**
   A. Operative report(s)
   B. Pathology report(s)
3. Resection and/or biopsy performed, but operative report(s) and pathology are not available (minimal information):
   A. Tumor Board
   B. Code from physician’s documentation of original diagnosis from operative or pathology report OR
   C. Physician’s documentation of primary site in the medical record
   **Example:** The patient had a biopsy done at another facility. The operative and pathology reports are not in the medical record. The attending documents that the patient had a biopsy of a cerebral meningioma at a different facility. Code the primary site cerebral meninges C700.
4. For cases diagnosed by imaging (no pathology/resection or biopsy) use information from scans in the following priority order:
   A. MRI
   B. CT
   C. PET
   D. Angiogram
5. See Table 2: Reportable Primary Sites to confirm the primary site is reportable.
6. When the primary site is cranial nerve OR cranial nerve meninges, see Table 3: Reportability of Non-Malignant Cranial Nerve (CN) Tumors to confirm the site of the tumor is intracranial (reportable) or extracranial (not reportable)
7. See Table 4: Non-Reportable Neoplasms for site/histology combinations and histologies that are not reportable.
8. When the primary site is brain or intracranial glands, see Table 5: Histologic Types of Non-Malignant Intracranial (Brain and Gland) Tumors to confirm site/histology combinations.

**Reportable Primary Site Groups**

The two major groups of reportable sites are:
1. **Intracranial** (within the skull/cranium)
2. **Spinal sites** (spinal meninges and sites within the spinal meninges)
Reportable Primary Sites and their ICD-O Codes

1. Intracranial (intra means inside or within; intracranial is inside the skull).
   A. **Cerebral/cranial dura/meninges** C700. The cerebral meninges has three layers:
      i. **Dura** mater is the superficial layer of meninges
         - Tightly adherent to skull
         - Contains folds and sinuses
         - Contacts **endosteum** which lines the bones of the skull
      ii. **Arachnoid** mater forms the middle of the three layers of meninges
      iii. **Pia** mater is the delicate vascular fibrous membrane which is adherent to the brain.
   B. **Brain** C710-C719
   C. **Crani al nerves** C722-C729. See **Table 3: Reportability of Non-Malignant Cranial Nerve (CN) Tumors**
   D. **Intracranial glands** C751-C753
      i. Craniopharyngeal duct C752
      ii. Pineal gland C753
      iii. Pituitary gland C751

2. **Spinal** sites: includes the **spinal meninges** and all structures within the meninges (Intradural, within/in the spinal meninges).
   A. The spinal meninges C701 covers/encloses the spinal nerve roots and the spinal cord.
   B. The spinal nerve roots **C470, C473, C475, C476** are the origin of the peripheral spinal nerves.
      **Note 1:** Only the nerve roots (the portion within the spinal meninges) are reportable. Tumors on portions of the peripheral nerves that have exited the spinal meninges are not reportable.
      **Note 2:** The most common nerve root tumors are schwannomas and neurilemoma.
      i. **Coccygeal** nerve, 1 pair. Code to peripheral nerves of pelvis C475
      ii. **Lumbar** nerve, 5 pair. Code to peripheral nerves of trunk C476
      iii. **Sacral** nerve, 5 pair. Code to peripheral nerves of pelvis C475
      iv. **Cervical** nerve/occipital nerve, 8 pair. Code to peripheral nerve of head, face, and neck C470
      v. **Thoracic** nerve, 12 pair. Code to peripheral nerves of thorax C473
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

Table 2: Reportable Primary Sites

<table>
<thead>
<tr>
<th>Site Group</th>
<th>Reportable Subsite Terms and Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brain</td>
<td>Brain NOS C719</td>
</tr>
<tr>
<td></td>
<td>Brain stem C717</td>
</tr>
<tr>
<td></td>
<td>Cerebellum NOS C716</td>
</tr>
<tr>
<td></td>
<td>Cerebrum C710</td>
</tr>
<tr>
<td></td>
<td>Frontal lobe C711</td>
</tr>
<tr>
<td></td>
<td>Occipital lobe C714</td>
</tr>
<tr>
<td></td>
<td>Overlapping lesion of brain and central nervous system C718</td>
</tr>
<tr>
<td></td>
<td>Parietal lobe C713</td>
</tr>
<tr>
<td></td>
<td>Temporal lobe C712</td>
</tr>
<tr>
<td></td>
<td>Ventricle NOS C715</td>
</tr>
</tbody>
</table>

Note 1: Sphenoid wing meningiomas are reportable. Primary site is coded to cerebral meninges C700 because they originate in the cerebral dura/meninges covering the sphenoid bone.

Note 2: Cavernous sinus neoplasms are reportable. These neoplasms arise in
- The dura/meninges surrounding the cavernous sinus and are coded to the cerebral meninges C700
- The cranial nerve(s) passing through the cavernous sinus and are coded to the specific cranial nerve when the origin is the cranial nerve
- The spinal dura/meninges when the origin is in the meninges (usually meningioma) C701

Note 3: There is no site code for cavernous sinus because the neoplasms within this sinus originate in the meninges, cranial nerves, or are encroaching into the cavernous sinus by direct extension from another site.

Column 1 lists the reportable primary site term.
Column 2 lists the site code for the reportable primary site.
### Site Group

<table>
<thead>
<tr>
<th>Cranial Nerves</th>
<th>Reportable Subsite Terms and Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abducent (cranial nerve VI)</td>
<td>C725</td>
</tr>
<tr>
<td>Accessory (cranial nerve XI)</td>
<td>C725</td>
</tr>
<tr>
<td>Acoustic (cranial nerve VIII)</td>
<td>C724</td>
</tr>
<tr>
<td>Cranial nerve NOS</td>
<td>C725</td>
</tr>
<tr>
<td>Facial (cranial nerve VII)</td>
<td>C725</td>
</tr>
<tr>
<td>Glossopharyngeal (cranial nerve IX)</td>
<td>C725</td>
</tr>
<tr>
<td>Hypoglossal (cranial nerve XII)</td>
<td>C725</td>
</tr>
<tr>
<td>Oculomotor (cranial nerve III)</td>
<td>C725</td>
</tr>
<tr>
<td>Olfactory (cranial nerve I)</td>
<td>C722</td>
</tr>
<tr>
<td>Optic (cranial nerve II)</td>
<td>C723</td>
</tr>
<tr>
<td>Trigeminal (cranial nerve V)</td>
<td>C725</td>
</tr>
<tr>
<td>Trochlear (cranial nerve IV)</td>
<td>C725</td>
</tr>
<tr>
<td>Vagus (cranial nerve X)</td>
<td>C725</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ill-Defined Sites Central Nervous System</th>
<th>Reportable Subsite Terms and Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nervous system NOS</td>
<td>C729</td>
</tr>
<tr>
<td>Overlapping lesion of brain and central nervous system</td>
<td>C728</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intracranial Duct and Glands</th>
<th>Reportable Subsite Terms and Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Craniopharyngeal duct</td>
<td>C752</td>
</tr>
<tr>
<td>Pineal gland</td>
<td>C753</td>
</tr>
<tr>
<td>Pituitary gland</td>
<td>C751</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Meninges</th>
<th>Reportable Subsite Terms and Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebral meninges</td>
<td>C700</td>
</tr>
<tr>
<td>Meninges NOS</td>
<td>C709</td>
</tr>
<tr>
<td>Spinal meninges</td>
<td>C701</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Spinal Sites</th>
<th>Reportable Subsite Terms and Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cauda equina/conus medullaris/filum terminale</td>
<td>C721</td>
</tr>
<tr>
<td>Meninges NOS</td>
<td>C709</td>
</tr>
<tr>
<td>Spinal meninges</td>
<td>C701</td>
</tr>
</tbody>
</table>
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

### Table 3: Reportability of Non-Malignant Cranial Nerve (CN) Tumors

This table is used to determine whether non-malignant cranial nerve tumors and cranial nerve meningiomas are reportable. When cranial nerves exit the intracranial space, they become peripheral nerves (non-reportable).

**Note 1:** A neoplasm arising in a cranial nerve is coded to the specific nerve in which it arises.
**Note 2:** Neoplasms, commonly meningiomas, arising in the dura/meninges of an intracranial nerve are coded to cerebral meninges C700.
**Note 3:** It is important to check the operative report to determine whether the surgery is intracranial or intradural.
**Note 4:** This table is used for non-malignant neoplasms ONLY.

**Column 1:** The proper name for the cranial nerve (CN) and the cranial nerve number  
**Column 2:** The point at which the nerve exits the cranium  
**Column 3:** Reportable portions of the cranial nerve. Of note, malignant neoplasms are reportable for all parts of the cranial nerves  
**Column 4:** Non-reportable portions of the cranial nerve

<table>
<thead>
<tr>
<th>Name and CN #</th>
<th>Exits Cranium Through</th>
<th>Reportable Portions of CN</th>
<th>Non-Reportable Portions of CN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cranial nerve NOS</td>
<td></td>
<td>Within cranium, unknown which nerve</td>
<td></td>
</tr>
<tr>
<td>C725</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Olfactory CN 1</td>
<td>Cribriform plate</td>
<td>Surface of the brain</td>
<td>Originates on the olfactory mucosa of nasal cavity, then travels through the cribriform plate of the ethmoid bone</td>
</tr>
<tr>
<td>C722</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Optic CN 2</td>
<td>Optic canal</td>
<td>Always reportable: CN2 is unique because it is intradural, covered with the meninges/dura and all portions are reportable.</td>
<td>After exiting the superior orbital fissure, the nerve enters the orbit.</td>
</tr>
<tr>
<td>Oculomotor CN 3</td>
<td>Superior orbital fissure</td>
<td>Originates in the midbrain.</td>
<td></td>
</tr>
<tr>
<td>C725</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Non-Malignant CNS Equivalent Terms and Definitions

**C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753**

**Peripheral nerves C470, C473, C475, C476 (for nerve roots only)**

<table>
<thead>
<tr>
<th>Name and CN #</th>
<th>Exits Cranium Through</th>
<th>Reportable Portions of CN</th>
<th>Non-Reportable Portions of CN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trochlear CN 4 C725</td>
<td>Superior orbital fissure</td>
<td>Arises from the <strong>dorsal brain stem</strong>, loops around the brainstem and passes anteriorly within the <strong>subarachnoid space</strong>. It travels between the <strong>superior cerebellar and posterior cerebral arteries</strong> and through the <strong>dura</strong>, enters <strong>cavernous sinus</strong>.</td>
<td>Enters the <strong>orbital fissure</strong>.</td>
</tr>
</tbody>
</table>
| Trigeminal CN 5 C725 | The ophthalmic, maxillary and mandibular branches leave the skull through three separate foramina, the superior orbital fissure, the foramen rotundum and the foramen ovale. | CN5 originates in the **pons**. Upon leaving the pons it enters a **small fossa** posterior and inferolateral to the cavernous sinus called **Meckel's (trigeminal) cave**. | • **Ophthalmic nerve branch** crosses the **pterygopalatine fossa**, inclines laterally on the back of the **maxilla**, and enters the **orbit** through the inferior orbital fissure where it is called the **infraorbital nerve**. It ends beneath the **quadatus labii superius**, and divides into multiple branches that spread to the side of the **nose**, the lower **eyelid**, and the upper **lip**  
• **Maxillary** nerve leaves foramen rotundum and traverses the **infraorbital groove** and **canal** in the floor of the **orbit**, and appears on the face at the infraorbital foramen.  
• **Mandibular** nerve leaves via the foramen ovale travels along the **mandibular groove** |
| Abducent CN 6 C725 | Cranial meninges | Exits brainstem at junction of **pons** and the **medulla**, enters the **subarachnoid space** and runs upward between the pons and the **clivus** entering the **cavernous sinus**. | **Dorello's canal** and travels to the tip of the **temporal bone**. Enters **orbit** |
## Non-Malignant CNS Equivalent Terms and Definitions

**C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753**  
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

<table>
<thead>
<tr>
<th>Name and CN #</th>
<th>Exits Cranium Through</th>
<th>Reportable Portions of CN</th>
<th>Non-Reportable Portions of CN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Facial CN 7</td>
<td>Internal acoustic</td>
<td>CN7 originates in the pons, along the posterior cranial fossa (the posterior cranial fossa is part of the intracranial cavity)</td>
<td>Enters the temple through the internal auditory meatus and runs through the facial canal.</td>
</tr>
<tr>
<td>C725</td>
<td>meatus</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acoustic or</td>
<td>Internal acoustic</td>
<td>Originates in the brain stem (medulla oblongata) between the base of the brain (pons) and the spinal cord</td>
<td></td>
</tr>
<tr>
<td>vestibulocochlear</td>
<td>meatus</td>
<td>Both the vestibular branch and the cochlear branch are located in the inner ear</td>
<td></td>
</tr>
<tr>
<td>CN 8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C724</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Glossopharyngeal | Jugular foramen     | Originates in the anterior portion of the medulla oblongata | Jugular foramen  
Between the internal jugular vein and internal carotid artery  
Lies on the stylopharyngeus and middle pharyngeal constrictor muscle  
Passes under the hypoglossus muscle  
Palatine tonsil  
Extends to mucous glands of the mouth, and base of the tongue |
| CN 9          |                       |                           |                              |
| C725          |                       |                           |                              |
### Non-Malignant CNS Equivalent Terms and Definitions

*C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753*

Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

<table>
<thead>
<tr>
<th>Name and CN #</th>
<th>Exits Cranium Through</th>
<th>Reportable Portions of CN</th>
<th>Non-Reportable Portions of CN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vagus CN 10</td>
<td>Jugular foramen</td>
<td>The vagus nerve originates from the <strong>medulla</strong> of the <strong>brainstem</strong>.</td>
<td>CN10 descends within the <strong>carotid sheath</strong> medial to the internal jugular vein at the root of the <strong>neck</strong>. The right vagus crosses in front of the subclavian artery and travels into the <strong>fat behind the blood vessels</strong>, reaching the <strong>thorax</strong>. It then inclines <strong>behind the hilum</strong> of the <strong>right lung</strong> and moves toward the esophagus. The nerve splits into the <strong>right</strong> and <strong>left</strong> vagus at the <strong>esophageal plexus</strong> forming the anterior and posterior <strong>gastric nerves</strong></td>
</tr>
<tr>
<td>C725</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Accessory CN 11</td>
<td>Jugular foramen</td>
<td>The spinal accessory nerve <strong>originates</strong> in the neurons of the upper spinal cord, specifically <strong>C1-C5/C6 spinal nerve roots</strong>. The nerve enters the foramen magnum or lateral aspect of the <strong>medulla oblongata</strong>. The fibers of the spinal accessory nerve coalesce to <strong>form spinal rootlets, roots</strong>, and finally the <strong>spinal accessory nerve itself</strong>.</td>
<td>The nerve <strong>exits</strong> the skull through the jugular foramen. It then runs along the internal <strong>carotid artery</strong> within the <strong>neck</strong> and reaches the <strong>sternocleidomastoid</strong> muscle and the <strong>trapezius</strong>.</td>
</tr>
<tr>
<td>C725</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypoglossal CN</td>
<td>Hypoglossal canal</td>
<td><strong>CN12</strong> starts in the <strong>hypoglossal</strong> nucleus of the <strong>brainstem</strong>,</td>
<td><strong>CN12</strong> exits the hypoglossal canal, traveling <strong>between the carotid</strong> artery and <strong>jugular</strong> vein, ending under the <strong>tongue</strong>.</td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>C725</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Non-Malignant CNS Equivalent Terms and Definitions  
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753  
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

### Table 4: Non-Reportable Neoplasms

Use **Table 4** for **non-malignant neoplasms ONLY**. The table identifies histology/site combinations which are **not reportable**. This table was created from WHO with the cooperation of the Central Brain Tumor Registry of the United States (CBTRUS).

<table>
<thead>
<tr>
<th>Non-reportable Histology Term</th>
<th>Non-reportable Histology Code</th>
<th>Definitions and Sites</th>
</tr>
</thead>
</table>
| Carcinomas                    | 8010-8060, 8071-8671, 8940-8941 | Brain C710-C719  
  **Site/histology edit** carcinomas/brain |
| Carcinomas                    | 8010-8671, 8940-8941 | Cerebral meninges, spinal meninges, meninges NOS C700-C709  
  **Site/histology edit** carcinomas/meninges |
| Carcinomas                    | 8010-8671, 8940-8941 | C721-C729 (Other central nervous system)  
  **Site/histology edit** carcinomas/other CNS |
| Colloid cyst                   | No code | |
| Epidermoid tumor/cyst         | No code | |
| Fibromoma                     | No code | |
| Glomus tympanicum, glomus jugulare | 8690/1 | These tumors occur in the inner ear, the aortic body and other paraganglia respectively; sites for which non-malignant tumors are **not reportable** |
| Hygroma                       | 9173/0 | |
| Hypothalamic hamartoma        | No code | Occurs in hypothalamus |
| Neurofibromatosis, type 1 (NF1) | No code* | Genetic disease that produces non-malignant tumors in the skin, brain, CNS, and other sites. The brain and CNS tumors spawned by NF1 are reportable, the genetic disease is not |
| Neurofibromatosis, type 2 (NF2) | No code* | Genetic disease that produces non-malignant tumors in the skin, brain, CNS, and other sites. The brain and CNS tumors produced by NF2 are reportable, the genetic disease is not |
| Neuroglial cyst                | No code | Ventrices |
| Osteochondroma                 | 9210/0 | Originates in the cartilage around bone, site not reportable for non-malignant neoplasms |
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

<table>
<thead>
<tr>
<th>Non-reportable Histology Term</th>
<th>Non-reportable Histology Code</th>
<th>Definitions and Sites</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rathke cleft cyst</td>
<td>No code</td>
<td>Sella turcica C751. This is a Rathke cleft CYST, not a Rathke cleft tumor.</td>
</tr>
<tr>
<td>Schwannomatosis</td>
<td>No code*</td>
<td>A form of neurofibromatosis newly named/discovered</td>
</tr>
</tbody>
</table>

*The code which is currently in ICD-O-3 for neurofibromatosis will not be used in ICD-O updates or in future ICD-O editions

Table 5: Histologic Types of Non-Malignant Intracranial (Brain and Glands) Tumors

Because non-malignant brain and gland tumors are less common, this table identifies histologies which occur in the brain C710-C719 and the glands within the cranium C751-C753. These histologies also appear in Table 6.

Use Table 5 to:
• Code primary site when the instructions in Section 2: Reportable Primary Sites and Histologies do not apply
• Confirm that a histology can/should be coded to brain or intracranial glands

<table>
<thead>
<tr>
<th>Histology Term and Code</th>
<th>Most Common Primary Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiocentric glioma 9431/1</td>
<td>Cerebrum C710</td>
</tr>
<tr>
<td>Choroid plexus papilloma 9390/0 (Capillary) hemangioblastoma 9161/1</td>
<td>Intraventricular site (lateral/third ventricle C715 and IV ventricle C717) Cerebellum C716, cerebrum (rare) C710</td>
</tr>
<tr>
<td>Craniopharyngioma 9350/1</td>
<td>Pituitary gland, sella turcica C751</td>
</tr>
<tr>
<td>Dermoid cyst 9084/0</td>
<td>Pineal gland C753, suprasellar C719</td>
</tr>
<tr>
<td>Desmoplastic infantile astrocytoma and ganglioglioma 9412/1</td>
<td>Cerebrum/supratentorial brain NOS C710</td>
</tr>
</tbody>
</table>
### Non-Malignant CNS Equivalent Terms and Definitions

**C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753**

**Peripheral nerves C470, C473, C475, C476 (for nerve roots only)**

<table>
<thead>
<tr>
<th>Histology Term and Code</th>
<th>Most Common Primary Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysembryoplastic neuroepithelial tumor (DNT) 9413/0</td>
<td>Cerebrum C710, temporal lobe C712</td>
</tr>
<tr>
<td>Dysplastic gangliocytoma 9493/0</td>
<td>Cerebellum C716</td>
</tr>
<tr>
<td>Meningioma (rare) 9530/0</td>
<td>Intraventricular C715</td>
</tr>
<tr>
<td>Myxopapillary ependymoma 9394/1</td>
<td>4th ventricle C717</td>
</tr>
<tr>
<td>Pilocytic astrocytoma/juvenile pilocytic astrocytoma 9421/1</td>
<td>Posterior fossa C719, cerebrum C710</td>
</tr>
<tr>
<td>Pineocytoma 9361/1</td>
<td>Pineal gland C753</td>
</tr>
<tr>
<td>Pituicytoma 9432/1</td>
<td>Pituitary gland C751, sella turcica C751, suprasellar C719</td>
</tr>
<tr>
<td>Pituitary adenoma 8272/0</td>
<td>Pituitary gland C751</td>
</tr>
<tr>
<td>Subependymal giant cell tumor (SEGA) 9384/1</td>
<td>Lateral ventricles C715</td>
</tr>
<tr>
<td>Subependymoma 9383/1</td>
<td>Intraventricular site (lateral/third ventricle, rare C715 and IV ventricle C717)</td>
</tr>
</tbody>
</table>
### Non-Malignant CNS Equivalent Terms and Definitions

C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

#### Table 6: Specific Histologies, NOS, and Subtypes/Variants

Use this table to identify reportable histologies, including specific, NOS, and the subtype/variant of that NOS when referenced in the Multiple Primary and Histology coding rules.

This table includes the more common non-malignant histologies which occur in the CNS.

**Column 1** contains specific and NOS histology terms.
- **Specific** histology terms do not have subtypes/variants
- **NOS** histology terms do have subtypes/variants.

**Column 2** contains synonyms for the specific or NOS term. Synonyms have the same histology code as the specific or NOS term.

**Column 3** contains subtypes/variants of the NOS histology. Subtypes/variants do not have the same histology code as the NOS term.

<table>
<thead>
<tr>
<th>NOS/Specific Histology Term and Code</th>
<th>Synonyms</th>
<th>Subtypes/Variants Histology Term and Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiocentric glioma 9431/1</td>
<td>Angiocentric neuroepithelial tumor Monomorphous angiocentric glioma</td>
<td></td>
</tr>
<tr>
<td>Benign fibrous histiocytoma 8830/0</td>
<td>Cerebellar liponeurocytoma Extraventricular neurocytoma</td>
<td></td>
</tr>
<tr>
<td>Central neurocytoma 9506/1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chondroma 9220/0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chordoid glioma of the third ventricle 9444/1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Choroid plexus papilloma 9390/0</td>
<td>Atypical choroid plexus papilloma 9390/1</td>
<td></td>
</tr>
<tr>
<td>Craniopharyngioma 9350/1</td>
<td>Adenomatous craniopharyngioma 9351/1 Papillary craniopharyngioma 9352/1</td>
<td></td>
</tr>
<tr>
<td>Desmoplastic infantile astrocytoma and ganglioglioma 9412/1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Jump to [Multiple Primary Rules](#)  
Jump to [Histology Coding Rules](#)  
Non-Malignant CNS Solid Tumor Rules 2018  
Updated 8/13/2018
### Non-Malignant CNS Equivalent Terms and Definitions

C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753

Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

<table>
<thead>
<tr>
<th>NOS/Specific Histology Term and Code</th>
<th>Synonyms</th>
<th>Subtypes/Variants Histology Term and Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dysembryoplastic neuroepithelial tumor 9413/0</td>
<td>DNT</td>
<td></td>
</tr>
<tr>
<td>Gangliocytoma 9492/0</td>
<td></td>
<td>Dysplastic cerebellar gangliocytoma/Lhermitte-Duclos disease 9493/0</td>
</tr>
<tr>
<td>Ganglioglioma 9505/1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Granular cell tumor of the sellar region 9582/0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemangioblastoma 9161/1</td>
<td>Capillary hemangioblastoma</td>
<td></td>
</tr>
<tr>
<td>Hemangioma 9120/0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leiomyoma 8890/0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipoma 8860/0</td>
<td></td>
<td>Hibernoma 8880/0</td>
</tr>
<tr>
<td>Meningeal melanocytosis 8728/0</td>
<td></td>
<td>Meningeal melanocytoma 8728/1</td>
</tr>
<tr>
<td>Meningioma 9530/0</td>
<td>Lymphoplasmacyte-rich meningioma Metaplastic meningioma Microcystic meningioma Secretory meningioma</td>
<td>Angiomatous meningioma 9534/0 Atypical meningioma 9539/1 Clear cell/chordoid meningioma 9538/1 Fibrous meningioma 9532/0 Meningothelial meningioma 9531/0 Transitional meningioma 9537/0</td>
</tr>
<tr>
<td>Myofibroblastoma 8825/0</td>
<td></td>
<td>Inflammatory myofibroblastic tumor 8825/1</td>
</tr>
<tr>
<td>Myxopapillary ependymoma 9394/1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neurofibroma 9540/0</td>
<td>Atypical neurofibroma</td>
<td>Plexiform neurofibroma 9550/0</td>
</tr>
<tr>
<td>Optic glioma/pilocytic astrocytoma 9421/1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Osteoma 9180/0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Papillary glioneuronal tumor 9509/1</td>
<td>Diffuse leptomeningeal glioneuronal tumor Rosette-forming glioneuronal tumor</td>
<td></td>
</tr>
<tr>
<td>Paraganglioma 8693/1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perineurioma 9571/0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

<table>
<thead>
<tr>
<th>NOS/Specific Histology Term and Code</th>
<th>Synonyms</th>
<th>Subtypes/Variants Histology Term and Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pineocytoma 9361/1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pituicytoma 9432/1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pituitary adenoma 8272/0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rhabdomyoma 8900/0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schwannoma 9560/0</td>
<td>Cellular schwannoma Neurilemoma Neurinoma Plexiform schwannoma</td>
<td>Melanotic schwannoma 9560/1</td>
</tr>
<tr>
<td>Solitary fibrous tumor Grade 1 8815/0</td>
<td>Hemangiopericytoma Grade 1</td>
<td>Solitary fibrous tumor/hemangiopericytoma Grade 2 8815/1</td>
</tr>
<tr>
<td>Spindle cell oncocytoma 8290/0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subependymal giant cell astrocytoma 9384/1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subependymoma 9383/1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Teratoma 9080/1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Conflicting Information on Pathology Report(s)

The classification of brain tumors is a subjective matter because definitive criteria have not been established/accepted. Pathologists may disagree on the histology or behavior.

Follow the steps below for coding the histology and/or behavior of tumor when there are discrepancies:

- When possible, get advice from the pathologist
- When possible, contact attending physician
- When possible, consult with registry advisor
- If none of those options are available, code the histology and grade from the most dependable source (see Priority List for Coding Histology).

The following are examples of how conflicting information occurs in single and in multiple pathology reports

- **Single pathology report:**
  - Multiple pathologists within the institution review the slides
  - Slides are sent for outside review and the information from the consulting lab conflicts with the original pathology report
- **Multiple pathology reports:** The first report is from a biopsy and the second report is from a resection. Code the histology and/or behavior from the resection.
Use **Table 7** to identify sites for which laterality **must** be coded. Do **not** use this table to determine multiple primaries.

<table>
<thead>
<tr>
<th>Paired Sites and Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acoustic nerve C724</td>
</tr>
<tr>
<td>Cerebral meninges C700</td>
</tr>
<tr>
<td>Cerebrum C710</td>
</tr>
<tr>
<td>Cranial nerves C725</td>
</tr>
<tr>
<td>Frontal lobe C711</td>
</tr>
<tr>
<td>Occipital lobe C714</td>
</tr>
<tr>
<td>Olfactory nerve C722</td>
</tr>
<tr>
<td>Optic nerve C723</td>
</tr>
<tr>
<td>Parietal lobe C713</td>
</tr>
<tr>
<td>Temporal lobe C712</td>
</tr>
</tbody>
</table>

**Note 1:** Midline tumors are most common for the following histologies: glioblastoma multiforme, meningiomas, lymphomas (usually located near the midline), and epidermoid cysts (which can cross the midline via the subarachnoid space).

**Note 2:** SEER allows laterality to be coded for sites other than those in the table.
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

Table 8: Non-Malignant CNS Tumors with the Potential of Transforming to Malignant Behavior

The word “transformation” as used in this table means that:

- Residual tumor becomes more aggressive /3 OR
- The tumor recurs as a more aggressive /3 histology

The table identifies non-malignant tumors that have the potential of transforming to a malignant tumor (new primary).

Use Table 8 when directed to by the Multiple Primary Rules.

**Column 1** is the non-malignant ICD-O histology term and code.

**Column 2** is the malignant /3 ICD-O histology term and code to which the non-malignant tumor can transform.

<table>
<thead>
<tr>
<th>Original Histology and Code</th>
<th>Transformed Histology and Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chondroma 9220/0</td>
<td>Chondrosarcoma 9220/3</td>
</tr>
<tr>
<td>Ganglioglioma 9505/1</td>
<td>Anaplastic ganglioglioma 9505/3</td>
</tr>
<tr>
<td>Hemangioma 9120/0</td>
<td>Angiosarcoma 9120/3</td>
</tr>
<tr>
<td>Hemangiopericytoma 9150/1</td>
<td>Anaplastic hemangiopericytoma 9150/3</td>
</tr>
<tr>
<td>Leiomyoma 8890/0</td>
<td>Leiomyosarcoma 8890/3</td>
</tr>
<tr>
<td>Lipoma 8850/0</td>
<td>Liposarcoma 8850/3</td>
</tr>
<tr>
<td>Osteoma 9180/0</td>
<td>Osteosarcoma 9180/3</td>
</tr>
<tr>
<td>Perineurioma 9571/0</td>
<td>Malignant perineurioma 9571/3</td>
</tr>
<tr>
<td>Rhabdomyoma 8900/0</td>
<td>Rhabdomyosarcoma 8900/3</td>
</tr>
<tr>
<td>Teratoma 9080/1</td>
<td>Immature teratoma 9080/3</td>
</tr>
<tr>
<td>Teratoma, mature 9080/0</td>
<td>Immature teratoma 9080/3</td>
</tr>
</tbody>
</table>
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

A.D.A.M illustration used with licensed permission. All rights reserved.
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)
Non-Malignant CNS Equivalent Terms and Definitions

C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)
Non-Malignant CNS Equivalent Terms and Definitions
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)
Non-Malignant CNS Multiple Primary Rules
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

Note 1: **Timing** is **not used** to determine multiple primaries.

Note 2: **Laterality** is **not used** to determine multiple primaries.

Note 3: **Malignant** central nervous system (CNS) tumors have a separate set of rules.

Note 4: 2007 MPH Rules and 2018 Solid Tumor Rules are used based on **date of diagnosis**.
- Tumors diagnosed 01/01/2007 through 12/31/2017: Use 2007 MPH Rules
- Tumors diagnosed 01/01/2018 and later: Use 2018 Solid Tumor Rules
- The original tumor diagnosed before 1/1/2018 and a subsequent tumor diagnosed 1/1/2018 or later in the same primary site: Use the 2018 Solid Tumor Rules.

### Unknown if Single or Multiple Tumors

**Rule M1** Abstract a **single primary** when it is not possible to determine if there is a single tumor or multiple tumors.

**Note 1:** Use this rule only after all information sources have been exhausted

**Note 2:** Examples of cases with minimal information include
- Death certificate only (DCO)
- Cases for which information is limited to pathology report only
- Outpatient biopsy with no follow-up information available
- Multiple pathology reports which do not specify whether a single tumor or multiple tumors have been biopsied and/or resected

This is the end of instructions for Unknown if Single or Multiple Tumors.

Prepare one abstract. Use the **histology rules** to assign the appropriate histology code.

### Single Tumor

**IMPORTANT:** The **major difference** between M3 and M5 is:

**M3:** No resection as first course of treatment AND when the same tumor is subsequently resected, pathology proves malignant behavior

**M5:** Tumor resected as first course of treatment. Subsequent tumor (recurrence or de novo) is malignant
Non-Malignant CNS Multiple Primary Rules
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

Rule M2  Abstract a **single primary** when there is a **single tumor**.

*Note 1:* A single tumor is **always** a single primary.
*Note 2:* The tumor may overlap onto or extend into an adjacent/contiguous site or subsite.
*Note 3:* The tumor may have multiple histologic components.
*Note 4:* The tumor may be diagnosed as borderline /1 on scans and subsequent pathology proves a benign /0 tumor.

*Example:* Patient has a MRI with a diagnosis of a benign /0 tumor. The pathology report from the subsequent surgery shows a borderline /1 tumor. This is a single tumor and a **single primary**. (It is the same tumor as seen on the MRI; better information is provided by the pathology report.)

Rule M3  Abstract a **single primary** (the malignant) when a single tumor meets the following two criteria:

1. The original diagnosis was non-malignant /0 or /1 **AND**
   - First course treatment was active surveillance (no tumor resection). Diagnosis was:
     - Clinical
     - Radiographic
     - Stereotactic biopsy
2. Subsequent resection pathology is malignant /3

*Note 1:* This is a **new rule** which **clarifies** that a single tumor is **always** a single primary and the malignant behavior is reported.
*Note 2:* Use the Malignant CNS and Peripheral Nerves Rules to code histology.
*Note 3:* The **resection pathology** is **more accurate** than clinical, radiographic or stereotactic biopsy information. While stereotactic biopsy provides a pathologic specimen, it is small and may not have included the malignant portion of tumor.
*Note 4:* There is **no time requirement** from initial diagnosis to resection.
*Note 5:* Edit the original abstract as follows:
   - **Do not** change date of diagnosis.
   - For cases which have been abstracted, **change behavior** code on original abstract from /0 or /1 to /3.
   - **Report** all data changes for cases which have been submitted to the central registry.
   - See the COC and SEER manuals for **instructions** on coding other data items such as Accession Year, Treatment and Sequence Number.

*Note 6:* The physician may have staged the non-malignant tumor at the time of original diagnosis (benign). The physician will also stage the malignant tumor. Staging and determining multiple primaries are done for different reasons. Staging determines which treatment would be most effective. Determining multiple primaries is done to stabilize the data for the study of epidemiology (long-term studies done on incidence, mortality, and causation of a disease with the goal of reducing or eliminating that disease).

*Example 1:* A patient is diagnosed by MRI with ganglioglioma 9505/1 in July 2009. After months of active surveillance (watchful waiting), the patient becomes **symptomatic**. A **resection** is done in April 2010; the **resection**
Non-Malignant CNS Multiple Primary Rules
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

pathology is anaplastic ganglioglioma 9505/3. Change behavior code on the original abstract from /1 to /3. Do not change date of diagnosis.

Example 2: A November 15, 2016 MRI and subsequent stereotactic biopsy of lateral ventricle of brain show a mature teratoma 9080/1. The patient becomes symptomatic in 2017 and the neoplasm is resected on October 31, 2017. The resection pathology diagnoses immature teratoma 9080/3. Change behavior code on the original abstract. Do not change date of diagnosis.

Rule M4  Abstract a single primary when a single benign tumor /0 transforms to an uncertain/borderline tumor /1. Timing is irrelevant. The tumors are:
- The same histology OR
- A NOS and a subtype/variant of that NOS

Note 1: Do not change the date of diagnosis OR the behavior code on the original abstract.

Note 2: This is a single tumor; single primary

Note 3: Both behaviors /0 and /1 are non-malignant; it is not necessary to change the original abstract.

Note 4: The physician may stage both tumors. Staging and determining multiple primaries are done for different reasons. Staging determines which treatment would be most effective. Determining multiple primaries is done to stabilize the data for the study of epidemiology (long-term studies done on incidence, mortality, and causation of a disease with the goal of reducing or eliminating that disease).

Note 5: For registries that collect recurrence data, document the transformed tumor as a recurrence.

Example 1: A choroid plexus papilloma NOS 9390/0 transforms to an atypical choroid plexus papilloma 9390/1. This is a single primary.

Example 2: A neurofibroma NOS 9540/0 transforms to neurofibromatosis NOS 9540/1.

Example 3: A meningioma 9530/0 transforms to an atypical meningioma 9539/1.

This is the end of instructions for Single Tumor.

I Prepare one abstract. Use the histology coding rules to assign the appropriate histology code.
Multiple Tumors

Note: Multiple tumors may be a single primary or multiple primaries.

IMPORTANT: The major difference between M3 and M5 is:

M3: No resection as first course of treatment AND when the same tumor is subsequently resected, pathology proves malignant behavior

M5: Tumor resected as first course of treatment. Subsequent tumor (recurrence or de novo) is malignant

Rule M5
Abstract multiple primaries when a malignant tumor /3 occurs after a non-malignant tumor /0 or /1 AND:

- The patient had a resection of the non-malignant tumor OR
- It is unknown/not documented whether a resection was done

Note: Abstract the second tumor (malignant) using the Malignant CNS rules.

Rule M6
Abstract a single primary when the patient has bilateral:

- Acoustic neuromas/ vestibular schwannomas 9560/0
- Optic gliomas/pilocytic astrocytomas 9421/1

Note 1: The bilateral tumors may appear simultaneously (at the same time) OR the contralateral tumor may be diagnosed at any time following the original diagnosis.

Note 2: WHO and IARC designate pilocytic astrocytoma as a synonym for optic glioma. When the primary site is optic nerve, the behavior is non-malignant.

Note 3: When the bilateral tumors are diagnosed at different times, the physician may stage each tumor because staging and determining multiple primaries are done for different reasons. Staging determines which course of treatment would be most effective. Determining multiple primaries is done to stabilize the data for the study of epidemiology (long-term studies done on incidence, mortality, and causation of a disease with the goal of reducing or eliminating that disease).
Non-Malignant CNS Multiple Primary Rules
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

Rule M7 Abstract multiple primaries when separate, non-contiguous tumors are two or more different subtypes/variants in Column 3, Table 6 in the Equivalent Terms and Definitions. Timing is irrelevant.
Note: The tumors may be subtypes/variants of the same or different NOS histologies.
- Same NOS: Atypical meningioma 9539/1 and fibrous meningioma 9532/0 are both subtypes of meningioma NOS 9530 but are distinctly different histologies. Abstract multiple primaries.
- Different NOS: Melanotic schwannoma 9560/1 is a subtype of schwannoma NOS 9560/0; papillary craniopharyngioma 9352/1 is a subtype of craniopharyngioma 9350/1. They are distinctly different histologies. Abstract multiple primaries.

Rule M8 Abstract a single primary when two or more separate/non-contiguous meningiomas arise in the cranial meninges. Laterality is irrelevant and may be any of the following combinations:
- The same laterality (left or right) of the cranial meninges
- Bilateral (both left and right) cranial meninges
- The midline AND in either the right or left cranial meninges
Note: This rule applies ONLY to meningiomas.

Rule M9 Abstract a single primary when there are separate/non-contiguous tumors in the brain (multicentric/multifocal) with the same histology XXXX. Tumors may be in any of the following locations and/or lateralities:
- Same laterality: In the same lobe; for example, two tumors in right temporal lobe C712 (same site code)
- Different lateralities of the same lobe; for example, left and right frontal lobes C711 (same site code)
- Different lobes; for example, parietal lobe C713 and occipital lobe C714 (different site codes)
Note 1: Metastases are never used to determine multiple primaries. Seeding metastasis is often noted in ependymomas.
Note 2: This is a change from clarification to previous rules.
Note 3: These rules are hierarchical. Use this rule ONLY when the previous rules do not apply.
Note 4: An example of a non-malignant brain tumor that may be multi-focal/multi-centric is hemangioblastoma 9161/1.
Note 5: The physician may stage each tumor because staging and determining multiple primaries are done for different reasons. Staging determines which course of treatment would be most effective. Determining multiple primaries is done to stabilize the data for the study of epidemiology (long-term studies done on incidence, mortality, and causation of a disease with the goal of reducing or eliminating that disease).
Non-Malignant CNS Multiple Primary Rules
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

Rule M10  Abstract a single primary when separate/non-contiguous tumors are on the same row in Table 6 in the Equivalent Terms and Definitions. Timing is irrelevant.

Note: The same row means the tumors are:
- The same histology (same four-digit ICD-O code) OR
- One is the preferred term (column 1) and the other is a synonym for the preferred term (column 2) OR
- A NOS (column 1/column 2) and the other is a subtype/variant of that NOS (column 3). NOS and subtype/variants are:
  - Choroid plexus papilloma 9390/0 and a subtype/variant of choroid plexus papilloma
  - Craniopharyngioma 9350/1 and a subtype/variant of craniopharyngioma
  - Gangliocytoma 9492/0 and a subtype/variant of craniopharyngioma
  - Lipoma 8860/0 and a subtype/variant of lipoma
  - Meningeal melanocytosis 8728/0 and a subtype/variant of meningeal melanocytosis
  - Meningioma 9530/0 and a subtype/variant of meningioma
  - Myofibroblastoma 8825/0 and a subtype/variant of myofibroblastoma
  - Neurofibroma 9540/0 and a subtype/variant of neurofibroma
  - Schwannoma 9560/0 and a subtype/variant of schwannoma
  - Solitary fibrous tumor WHO Grade 1 8815/0 and a subtype/variant of solitary fibrous tumor WHO Grade 1

Rule M11  Abstract multiple primaries when separate/non-contiguous tumors are on different rows in Table 6 in the Equivalent Terms and Definitions. Timing is irrelevant.

Note: Each row in the table is a distinctly different histology.

Rule M12  Abstract multiple primaries when multiple tumors are present in any of the following sites:
- Any lobe(s) of the brain C710-C719 AND any other part of CNS
- Cerebral meninges C700 AND spinal meninges C701
- Cerebral meninges C700 AND any other part of CNS
- Any cranial nerve(s) C721-C725 AND any other part of the CNS
- Meninges of cranial or peripheral nerves C709 AND any other part of the CNS
- Spinal meninges C701 AND any other part of CNS
Non-Malignant CNS Multiple Primary Rules
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

Rule M13  Abstract a single primary\(^1\) when the tumors do not meet any of the above criteria.

*Note:* These rules are hierarchical. Use this rule **ONLY** when the previous rules do not apply.

This is the end of instructions for Multiple Tumors

\(^1\) Prepare one abstract. Use the histology coding rules to assign the appropriate histology code. For registries collecting recurrence data:
When a subsequent tumor is “single primary,” record that subsequent tumor as a recurrence.

\(^{ii}\) Prepare two or more abstracts. Use the histology coding rules to assign the appropriate histology code to each case abstracted.
Non-Malignant CNS Histology Rules  
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753  
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

**Note 1:** Non-malignant central nervous system (CNS) neoplasms (previously called benign and borderline) are reportable for cases diagnosed 1/1/2004 and later.

**Note 2:** Malignant central nervous system (CNS) tumors have a separate set of rules.

**Note 3:** These rules are not used for tumor(s) or neoplasm(s) described as metastatic/metastasis.

**Note 4:** For rules specifying a NOS and a subtype/variant of the NOS, the NOS may be the preferred/most common term OR any of the synonyms for the NOS.

---

**Priority Order for Using Documentation to Identify Histology**

The priority list is used for single primaries (including multiple tumors abstracted as a single primary).

**This is a hierarchical list of source documentation:**

1. **Pathology/tissue** from resection  
   A. Biomarkers  
      **Note 1:** Biomarkers do not identify all histologic types.  
      **Note 2:** Biomarkers are not listed because they change rapidly.  
      **Example 1:** The genetic test 1p/19q is useful in diagnosing oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma, anaplastic oligoastrocytomas.  
      **Example 2:** BRAF will help determine whether a tumor is a pilocytic astrocytoma or a non-pilocytic astrocytoma.  
   B. The addendum and/or comments  
   C. Final diagnosis  
   D. CAP protocol/summary  
2. **Pathology/tissue** from biopsy  
   A. Biomarkers  
      **Note 1:** Biomarkers do not identify all histologic types.  
      **Note 2:** Biomarkers are not listed because they change rapidly.  
      **Example 1:** The genetic test 1p/19q is useful in diagnosing oligodendroglioma, anaplastic oligodendroglioma, oligoastrocytoma, anaplastic oligoastrocytomas.  
      **Example 2:** BRAF will help determine whether a tumor is a pilocytic astrocytoma or a non-pilocytic astrocytoma.  
   B. The addendum and/or comments  
   C. Final diagnosis
Non-Malignant CNS Histology Rules
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

D. CAP protocol/summary
   Note 1: Addendums and comments are given the highest priority because they often contain information about molecular testing, genetic testing, and/or special stains which give a more specific diagnosis.
   Note 2: The pathologist’s diagnosis is always the most reliable, so the final diagnosis is the second priority.
   Note 3: Do not use the microscopic or gross section of the pathology report for coding.
   Note 4: The CAP protocol is a checklist which
   - Provides guidelines for collecting the essential data elements for complete reporting of tumors and optimal patient care.
   - Allows physicians to check multiple histologies

   Note: The CAP summary must be documented in one location. It is usually found in:
   - The pathology final diagnosis OR
   - An addendum to the path report

3. Cytology (most frequently spinal fluid)
4. Radiography: The following list is in priority order.
   A. MRI
   B. CT
   C. PET
   D. Angiogram
5. Clinical Diagnosis: Code the histology documented by the physician when none of the above are available. Priority for using documentation:
   A. Documentation from Tumor Board
   B. References to pathology diagnosis
   C. Physician’s reference to type of cancer (histology) in the medical record

   Note: Code the specific histology when documented.
1. **Code** the histology when the:
   A. **Exact term is documented OR**
   B. **Histology is described as**
      - Subtype
      - Type
      - Variant

2. **Do not** code the histology when:
   A. The following modifiers are used as a descriptor:
      - Architecture
      - Differentiation
        **Note:** Only **code differentiation** when there is a **specific code** for the NOS with differentiation in Table 6 in the Equivalent Terms and Definitions, ICD-O and all updates.
      - Features (of)/with features of
        **Note:** Only **code features** when there is a **specific code** for the NOS with features in Table 6 in the Equivalent Terms and Definitions, ICD-O and all updates.
      - Foci; focus, focal
      - Major/majority of
        **Note:** Major/majority describes the greater amount of tumor.
      - Pattern(s)
      - Predominantly
        **Note:** Predominantly describes the greater amount of tumor.
   B. The following ambiguous terms are used as a descriptor:
      - Apparently
      - Appears
      - Comparable with
      - Compatible with
      - Consistent with
      - Favor(s)
      - Malignant appearing
Non-Malignant CNS Histology Rules
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

- Most likely
- Presumed
- Probable
- Suspect(ed)
- Suspicious (for)
- Typical (of)

Note 1: See SEER Program Manual and COC Manual. Ambiguous terminology is used to determine reportability.

Note 2: Histology described by ambiguous terminology is coded ONLY when a case is accessioned based on ambiguous terminology and no other histology information is available/documentated.

### Single Tumor

**Rule H1**  Code meningioma 9530/0 when the diagnosis is any of the following:
- Benign meningioma
- Lymphoplasmacyte-rich meningioma
- Meningioma with no mention of behavior
- Metaplastic meningioma
- Microcystic meningioma
- Secretory meningioma

*Note: Do not report a malignant /3 meningioma based on:
- Invasion of the skull bone
- Tumor extension through the foramina at the base of the skull

* Do not report a malignant /3 meningioma based on tumor extension to brain

**Rule H2**  Code the reportable CNS tumor (Table 6 in the Equivalent Terms and Definitions) when a patient has any of the following:
- Neurofibromatosis type 1 (NF1)
- Neurofibromatosis type 2 (NF2)
- Schwannomatosis

*Note 1: Only report tumors such as:
- Plexiform neurofibroma (usually NF1)

Jump to Equivalent Terms and Definitions
Jump to Multiple Primary Rules
Non-Malignant CNS Histology Rules
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

- Tumors of brain and spinal cord, meningiomas of cranial or spinal dura, glioma (usually NF2)

**Note 2:** Tumors are reportable when they meet the behavior code, site, and histology reportability requirements (see Reportability Criteria). **Do not** code neurofibromatosis.

**Note 3:** NF1 is a genetic disorder causing lesions in the skin, nervous system and skeleton.

**Note 4:** NF2 is a central form of the genetic disease and produces CNS tumors such as vestibular tumors, meningiomas, and ependymomas. When tumors meet the behavior code, site, and histology reportability requirements (see Reportability Criteria) those tumors are reportable.

**Note 5:** Schwannomatosis is a newer term for a distinct subtype/variant of the genetic diseases NF1 and NF2.

**Example:** Patient presents with vestibular schwannoma (acoustic neuroma). Genetic testing proves the patient has NF2. Report the acoustic nerve neuroma.

**Rule H3** Code the histology when only one histology is present.

**Note 1:** Use Table 6 to code histology. New codes, terms, and synonyms are included in Table 6 and coding errors may occur if the table is not used.

**Note 2:** When the histology is not listed in Table 6 use the ICD-O and all updates.

**Note 3:** Submit a question to Ask a SEER Registrar when the histology code is not found in Table 6, ICD-O or all updates.

**Rule H4** Code the subtype/variant when there is a NOS and a single subtype/variant of that NOS, such as the following:

- Choroid plexus papilloma 9390/0 and a subtype/variant of choroid plexus papilloma
- Craniopharyngioma 9350/1 and a subtype/variant of craniopharyngioma
- Gangliocytoma 9492/0 and a subtype/variant of gangliocytoma
- Lipoma 8860/0 and a subtype/variant of lipoma
- Meningeal melanocytosis 8728/0 and a subtype/variant of meningeal melanocytosis
- Meningioma 9530/0 and a subtype/variant of meningioma
- Myofibroblastoma 8825/0 and a subtype/variant of myofibroblastoma
- Neurofibroma 9540/0 and a subtype/variant of neurofibroma
- Schwannoma 9560/0 and a subtype/variant of schwannoma
- Solitary fibrous tumor WHO Grade 1 8815/0 and a subtype/variant of solitary fibrous tumor WHO Grade 1

**Note:** Use Table 6 in the Equivalent Terms and Definitions to identify the NOS and subtypes/variants of the NOS.

This is the end of instructions for Single Tumor.

Code the histology according to the rule that fits the case.
Non-Malignant CNS Histology Rules
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

Multiple Tumors Abstracted as a Single Primary

**Rule H5** Code meningioma 9530/0 when there are multiple meningiomas with the following diagnosis:
- Benign meningioma
- Lymphoplasmacyte-rich meningioma
- Meningioma with no mention of behavior
- Metaplastic meningioma
- Microcystic meningioma
- Secretory meningioma

*Note: Do not report a malignant* meningioma based on tumor extension/tumor expansion such as:
- Invasion of the skull bone
- Tumor extension through the foramina at the base of the skull
- Tumor extension to brain

**Rule H6** Code meningioma 9530/1 when there are multiple meningiomas of uncertain behavior.

*Note 1:* This is a rare condition that is usually associated with neurofibromatosis type 2 (NF2) and other genetic disorders.

*Note 2:* Use this code only for meningiomas with uncertain behavior; do not use this code for multiple benign or malignant meningiomas.

*Note 3:* It is not necessary for all tumors to be biopsied to use this code.

**Rule H7** Code the reportable CNS tumor (Table 6 in the Equivalent Terms and Definitions) when a patient has any of the following:
- Neurofibromatosis type 1 (NF1)
- Neurofibromatosis type 2 (NF2)
- Schwannomatosis

*Note 1:* Only report tumors such as:
- Plexiform neurofibroma (usually NF1)
- Tumors of brain and spinal cord, meningiomas of cranial or spinal dura, glioma (usually NF2)

*Note 2:* Tumors are reportable when they meet the behavior code, site, and histology reportability requirements (see Reportability Criteria). Do not code neurofibromatosis.

*Note 3:* NF1 is a genetic disorder causing lesions in the skin, nervous system and skeleton.
Non-Malignant CNS Histology Rules
C700, C701, C709, C710-C719, C721-C725, C728, C729, C751-C753
Peripheral nerves C470, C473, C475, C476 (for nerve roots only)

**Note 4:** NF2 is a central form of the genetic disease and produces CNS tumors such as vestibular tumors, meningiomas, and ependymomas. When tumors meet the behavior code, site, and histology reportability requirements (see Reportability Criteria) those tumors are reportable.

**Note 5:** Schwannomatosis is a newer term for a distinct subtype/variant of the genetic diseases NF1 and NF2.

**Example:** Patient presents with bilateral vestibular schwannoma (acoustic neuroma). Genetic testing proves the patient has NF2. Report the acoustic nerve neuromas 9560/0.

**Rule H8**
Code the histology when only **one histology** is present in all tumors.

**Note 1:** Use Table 6 to code histology. New codes, terms, and synonyms are included in Table 6 and coding errors may occur if the table is not used.

**Note 2:** When the histology is **not listed** in Table 6 use the ICD-O and all updates.

**Note 3:** Submit a question to Ask a SEER Registrar when the histology code is not found in Table 6, ICD-O or all updates.

**Rule H9**
Code the **subtype/variant** when there is a NOS and a **single subtype/variant** of that NOS present in all tumors, such as the following:

- Choroid plexus papilloma 9390/0 and a subtype/variant of choroid plexus papilloma
- Craniopharyngioma 9350/1 and a subtype/variant of craniopharyngioma
- Gangliocytoma 9492/0 and a subtype/variant of gangliocytoma
- Lipoma 8860/0 and a subtype/variant of lipoma
- Meningeal melanocytosis 8728/0 and a subtype/variant of meningeal melanocytosis
- Meningioma 9530/0 and a subtype/variant of meningioma
- Myofibroblastoma 8825/0 and a subtype/variant of myofibroblastoma
- Neurofibroma 9540/0 and a subtype/variant of neurofibroma
- Schwannoma 9560/0 and a subtype/variant of schwannoma
- Solitary fibrous tumor WHO Grade 1 8815/0 and a subtype/variant of solitary fibrous tumor WHO Grade 1

**Note:** Use Table 6 in the Equivalent Terms and Definitions to identify the NOS and subtypes/variants.

This is the end of instructions for Multiple Tumors Abstracted as a Single Primary.

**Code the histology according to the rule that fits the case.**